Laboratory Corporation of America Holdings

Monogram Biosciences, Inc.

Signe Fransen

Wei Huang

Neil T Parkin

Christos J Petropoulos

Jeannette Whitcomb

Ellen Paxinos

Jonathan Toma

Soumi Gupta

The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.

Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy

This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus ('HIV') to the non-nucleoside reverse transcriptase inhibitors ('NNRTIs') efavirenz (&#x201c;EFV&#x201d;), nevirapine (&#x201c;NVP&#x201d;), and delavirdine (&#x201c;DLV&#x201d;), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.

Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs

Growing community of inventors

San Francisco, CA, United States of America

Signe Fransen